HCM
PLX icon

Highbridge Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Highbridge Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-69,800
Closed -$73K – 549
2022
Q3 		$73K Buy
69,800
+13,800
+25% +$15.3K ﹤0.01% 540
2022
Q2 		$61K Buy
+56,000
New +$65.5K ﹤0.01% 648

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highbridge Capital Management's PLX Position: Q1 2023 in Review

Highbridge Capital Management sold out of Protalix BioTherapeutics (PLX) in Q1 2023, closing a stake of 2,413,487 shares — an estimated $3.31M sold.

Highbridge Capital Management first reported a position in PLX in Q4 2013 and held it in 9 quarters. The position peaked at $11.3M in Q1 2020. 34 funds tracked by Wall St. Rank hold PLX as of Q1 2023.

  • Highbridge Capital Management reported no remaining Protalix BioTherapeutics position as of Q1 2023 after selling out during the quarter.
  • Highbridge Capital Management sold 2,413,487 Protalix BioTherapeutics shares in Q1 2023, an estimated $3.31M.
  • Highbridge Capital Management first reported a position in Protalix BioTherapeutics in Q4 2013 and held it in 9 quarters.
  • Highbridge Capital Management's Protalix BioTherapeutics position peaked at $11.3M in Q1 2020.
  • 34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2023.

Based on Highbridge Capital Management's 13F filing for Q1 2023, filed 11 May 2023.